Summary:

• The global nuclear medicine radioisotopes market size reached USD 7.3 Billion in 2023.
• The market is expected to reach USD 14.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.51% during 2024-2032.
• Diagnostics (technetium-99m (Tc-99m) leads the market, accounting for the majority of the market share owing to its widespread use in diverse imaging applications.
• Cardiology represents the leading application segment spurred by increasing demand for non-invasive cardiac diagnostic techniques.
• Based on the end-user, the market is divided into hospitals, diagnostic centers, specialty clinics, education and research institutes, and others.
• North America leads the market with its high adoption of advanced nuclear medicine technologies.
• The growth of the nuclear medicine radioisotopes market is driven by increasing government funding and initiatives to promote nuclear medicine research and development.
• Collaborations between pharmaceutical companies and research institutions are bolstering the development of novel radiopharmaceuticals, expanding their clinical applications.

Request for a sample copy of this report: https://www.imarcgroup.com/nuclear-medicine-radioisotopes-market/requestsample

Industry Trends and Drivers:

• The increasing prevalence of chronic diseases:

The growing incidence of chronic diseases, particularly cancer and cardiovascular disorders, is a key driver of the nuclear medicine radioisotopes market. With the global aging population, these conditions have become more prevalent, and nuclear medicine plays a critical role in their diagnosis and treatment. For instance, radiopharmaceuticals are widely used in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) scans to detect and monitor cancer, heart diseases, and neurological conditions. As the need for early and accurate diagnosis intensifies, so does the demand for radioisotopes such as Technetium-99m (Tc-99m), which is extensively used for diagnostic purposes.

• Significant advancements in imaging technology:

Advancements in imaging technologies have significantly contributed to the expansion of the nuclear medicine radioisotopes market. Innovations such as hybrid imaging systems, which combine PET or SPECT with computed tomography (CT) or magnetic resonance imaging (MRI), have improved the accuracy of diagnostic procedures, making nuclear imaging more effective and efficient. These technological breakthroughs enable better localization and visualization of abnormalities, thus increasing the reliance on radioisotopes in clinical settings. The integration of new isotopes and the development of more sophisticated imaging agents are further boosting the market, as healthcare providers seek to offer improved diagnostic capabilities.

• The rising demand for targeted radiotherapy:

The rising demand for targeted radiotherapy is another major factor propelling the nuclear medicine radioisotopes market. Unlike traditional radiation therapy, targeted radiotherapy uses radiopharmaceuticals that deliver radiation directly to cancer cells, minimizing damage to surrounding healthy tissues. This approach has gained traction, especially in the treatment of cancers like prostate and neuroendocrine tumors. Radioisotopes such as Lutetium-177 and Iodine-131 are commonly used for targeted therapies, and ongoing research into novel radiopharmaceuticals is expanding their application. The growing preference for these minimally invasive treatments is driving the demand for therapeutic radioisotopes in oncology and other medical fields.

Nuclear Medicine Radioisotopes Market Report Segmentation:

We explore the factors propelling the nuclear medicine radioisotopes market growth, including technological advancements, consumer behaviors, and regulatory changes.

Breakup By Product:

• Diagnostics 
  • Technetium-99m (Tc-99m)
  • Gallium-67
  • Thallium-201
  • Fluorine-18
  • Others
• Therapeutics
  • Rhenium-186
  • Iodine-131
  • Samarium-153
  • Yttrium-90
  • Others

Diagnostics (technetium-99m (Tc-99m) represented the largest segment because it is widely used due to its efficiency in diagnostic imaging, offering precise results with minimal radiation exposure.

Breakup By Application:

• Cardiology
• Oncology
• Thyroid
• Neurology
• Others

Nuclear cardiology, particularly through SPECT imaging, is essential for diagnosing coronary artery disease, driving significant demand for radiopharmaceuticals in this application.

Breakup By End User:

• Hospitals
• Diagnostic Centers
• Specialty Clinics
• Education and Research Institutes
• Others

Based on the end-user, the market is divided into hospitals, diagnostic centers, specialty clinics, education and research institutes, and others.

Breakup By Region:

• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Argentina, Colombia, Chile, Peru, Others)
• Middle East and Africa ( Turkey, Saudi Arabia, Iran, United Arab Emirates, Others)

 North America leads the market with its advanced healthcare infrastructure, high prevalence of chronic diseases, and significant investment in nuclear medicine research drive its market leadership.

Top Nuclear Medicine Radioisotopes Market Leaders:

The nuclear medicine radioisotopes market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies.

Some of the key players in the market are:

• Bracco S.p.A.
• Bruce Power Inc.
• Cardinal Health Inc.
• China Isotope Radiation Corporation (China National Nuclear Corporation)
• Curium Pharma
• Eckert Ziegler
• Nordion (Canada) Inc (Sotera Health Company)
• NorthStar Medical Radioisotopes, LLC
• NTP Radioisotopes SOC Ltd.
• Shine Technologies LLC

Ask Analyst Browse full report with TOC List of Figures: https://www.imarcgroup.com/request?type=reportid=7532flag=C

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145